News
What's moving in GLP-1 right now.
Trial readouts, FDA decisions, supply updates — translated for humans.
NewsMay 6, 2026 · 2 min read
FDA Posts Liver Failure Report Linked to Lilly's Foundayo
A single liver failure case in the FDA adverse event database briefly knocked Lilly stock; analysts and Lilly say one report is not a safety signal.
Read more
NewsMay 6, 2026 · 2 min read
Mounjaro Dethrones Keytruda as World's Top-Selling Drug
Eli Lilly's tirzepatide franchise pulled in $36.5B in 2025, edging past Merck's Keytruda — the first time a GLP-1 has held the global No. 1 sales spot.
Read more
NewsMay 6, 2026 · 2 min read
Wegovy Pill's Q1 Sales Double Estimates, Novo Hikes Guidance
Novo Nordisk's oral Wegovy pulled in $354M in its first full quarter — twice analyst forecasts — and the company raised full-year guidance on the strength.
Read more
NewsApril 22, 2026 · 1 min read
Retatrutide Phase 3: 24% Weight Loss in TRIUMPH-3
Eli Lilly's triple-agonist retatrutide hit primary endpoints in TRIUMPH-3 — highest dose group lost nearly a quarter of body weight in under a year.
Read more